Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

× No keyword cloud information.

17 in total

1. Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica--a prospective study on the influence of glucocorticoid therapy.

Authors: U Lange; B Boss; J Teichmann; H Stracke; G Neeck
Journal: Z Rheumatol Date: 2000 Impact factor: 1.372

2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Authors: D E Furst; E C Keystone; J Braun; F C Breedveld; G R Burmester; F De Benedetti; T Dörner; P Emery; R Fleischmann; A Gibofsky; J R Kalden; A Kavanaugh; B Kirkham; P Mease; J Sieper; N G Singer; J S Smolen; P L C M Van Riel; M H Weisman; K Winthrop
Journal: Ann Rheum Dis Date: 2012-04 Impact factor: 19.103

3. Generalised bone loss in patients with early rheumatoid arthritis.

Authors: A K Gough; J Lilley; S Eyre; R L Holder; P Emery
Journal: Lancet Date: 1994-07-02 Impact factor: 79.321

4. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors: S van der Linden; H A Valkenburg; A Cats
Journal: Arthritis Rheum Date: 1984-04

5. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.

Authors: R B Kimble; S Bain; R Pacifici
Journal: J Bone Miner Res Date: 1997-06 Impact factor: 6.741

6. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.

Authors: M Vis; E A Havaardsholm; G Haugeberg; T Uhlig; A E Voskuyl; R J van de Stadt; B A C Dijkmans; A D Woolf; T K Kvien; W F Lems
Journal: Ann Rheum Dis Date: 2006-04-10 Impact factor: 19.103

7. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.

Authors: P Ammann; R Rizzoli; J P Bonjour; S Bourrin; J M Meyer; P Vassalli; I Garcia
Journal: J Clin Invest Date: 1997-04-01 Impact factor: 14.808

8. [Genetic aspects of osteopenia/osteoporosis in ankylosing spondylitis].

Authors: U Lange; J Teichmann; B Obermayer-Pietsch
Journal: Z Orthop Unfall Date: 2009 Sep-Oct Impact factor: 0.923

Review 9. Osteoporosis in patients with rheumatic diseases.

Authors: V L Star; M C Hochberg
Journal: Rheum Dis Clin North Am Date: 1994-08 Impact factor: 2.670

10. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha.

Authors: F Allali; M Breban; R Porcher; J F Maillefert; M Dougados; C Roux
Journal: Ann Rheum Dis Date: 2003-04 Impact factor: 19.103

12 in total

1. Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.

Authors: Kazutaka Masamoto; Bungo Otsuki; Shunsuke Fujibayashi; Koichiro Shima; Hiromu Ito; Moritoshi Furu; Motomu Hashimoto; Masao Tanaka; Stephen Lyman; Hiroyuki Yoshitomi; Shimei Tanida; Tsuneyo Mimori; Shuichi Matsuda
Journal: Eur Spine J Date: 2017-11-28 Impact factor: 3.134

Review 2. [Rheumatism and bone metabolism].

Authors: G Dischereit; U Lange
Journal: Orthopade Date: 2019-11 Impact factor: 1.087

3. Bone mass in axial spondyloarthritis: A literature review.

Authors: Erkan Kilic; Salih Ozgocmen
Journal: World J Orthop Date: 2015-03-18

4. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.

Authors: Takeshi Mochizuki; Koichiro Yano; Katsunori Ikari; Kosei Kawakami; Ryo Hiroshima; Naoko Koenuma; Mina Ishibashi; Shigeki Momohara
Journal: J Bone Miner Metab Date: 2017-07-05 Impact factor: 2.626

Review 5. [Inflammation and bone metabolism].

Authors: E Neumann; U Müller-Ladner; K W Frommer
Journal: Z Rheumatol Date: 2014-05 Impact factor: 1.372

6. Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.

Authors: Sevgi Baspinar; Mehmet Kırnap; Osman Baspınar; Oguzhan Sıtkı Dizdar; Derya Kocer
Journal: Rheumatol Int Date: 2016-07-21 Impact factor: 2.631

7. Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment.

Authors: Yu Mori; Yoshiyuki Kuwahara; Shinpei Chiba; Atsushi Kogre; Kazuyoshi Baba; Masayuki Kamimura; Eiji Itoi
Journal: J Bone Miner Metab Date: 2015-09-14 Impact factor: 2.626

Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.